Qiming Venture Partners Wins LP Advisory's 2024 Top 3 Venture Capital Firm Award
The ranking aims to reveal the actual exit performance of VC/PE funds and institutions, serving as a critical data benchmark for LPs to evaluate fund performance and institutional investment capabilities.
Recently, LP投顾 officially released its VC/PE Real Money Rankings. The rankings include the Top 50 Venture Capital Firms of 2024, the Top 50 Private Equity Firms of 2024, the Top 50 Venture Capital Firms (2020–2024), and the Top 50 Private Equity Firms (2020–2024). Qiming Venture Partners ranked 3rd among venture capital firms for 2024 and 11th for the 2020–2024 period.
Qiming Venture Partners
Honored with
2024 Top 3 Venture Capital Firm
2020–2024 Top 11 Venture Capital Firm
· VC/PE Real Money Rankings
By compiling, analyzing, and researching authoritative data released by the China Securities Regulatory Commission and stock exchanges, LP投顾 can accurately assess the true exit scale, strategy, and returns of VC/PE funds and institutions — serving as a key data benchmark for LPs to evaluate fund performance and institutional investment capability.
Based on LP投顾's 2024 statistics on VC/PE exits, the STAR Market remains the primary exit channel for institutions. Going forward, the STAR Market and ChiNext will continue to be among the main boards generating IPO deals.
Source | LP投顾
Past Highlights
Qiming Honors | Qiming Venture Partners Named to LP投顾 "Specialized and Innovative GP Ranking" 2023 Venture Capital Firm Qiming Headlines | Qiming Venture Partners and Portfolio Companies Win Multiple Awards Including ChinaVenture 2024 Top 5 Best Venture Capital Firm Qiming Honors | Qiming Venture Partners Ranks 5th in Zero2IPO 2024 China Venture Capital Firms and Wins Four Other Awards
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, and others.